Could a simple additive make nerve blocks last longer after chest surgery?

NCT ID NCT05851768

Recruiting now Symptom relief Sponsor: National Cancer Institute, Egypt Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests whether adding either dexmedetomidine or magnesium sulphate to the standard numbing medicine bupivacaine improves pain control after chest surgery. About 60 adults with cancer undergoing thoracotomy will receive one of three nerve-block combinations. The main goal is to see which approach reduces the total amount of morphine needed in the first 24 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bupivacaine with either dexmedetomidine or magnesium sulphate
What this could lead to: If one adjuvant works better, it could offer longer-lasting pain relief and reduce the need for morphine after chest surgery.
What could go wrong: This is a small, early-stage comparison; results may not apply to all patients, and side effects from the added drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANALGESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANALGESIA

Contacts and locations

Locations

Walaa Y Elsabeeny
RECRUITING

Cairo, 11796, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.